Todd Sisitsky - IQVIA Holdings Independent Director
| IQV Stock | USD 223.37 1.23 0.55% |
Director
Mr. Todd B. Benjamin Sisitsky is Independent Director of the Company since October 2016 and served as a director of predecessor company IMS Health since 2010. Mr. Sisitsky is the CoManaging Partner of TPG Capital, TPGs scale private equity business in the U.S. and Europe, and coleads the firms investment activities in the healthcare services and pharmaceutical and medical device sectors. He also serves on the executive committee of TPG Holdings. He has played leadership roles in connection with TPGs investments in Allogene Therapeutics, Adare Pharmaceuticals, Aptalis, Biomet, Exactech, Fenwal, Healthscopt, Iasis Healthcare, Immucor, IQVIA, Par pharmaceutical, and Surgical Care Affiliates. Prior to joining TPG in 2003, Mr. Sisitsky worked at Forstmann Little Company and Oak Hill Capital Partners. He received an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude. Mr. Sisitsky currently serves as the chair of the Dartmouth Medical School board of advisors, and as a board member of the international nonprofit Grassroot Soccer. Because of his extensive experience in leadership, business and healthcare, since 2016.
| Age | 49 |
| Tenure | 8 years |
| Address | 2400 Ellis Road, Durham, NC, United States, 27703 |
| Phone | 919 998 2000 |
| Web | https://www.iqvia.com |
IQVIA Holdings Management Efficiency
The company has Return on Asset of 0.0498 % which means that on every $100 spent on assets, it made $0.0498 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2287 %, implying that it generated $0.2287 on every 100 dollars invested. IQVIA Holdings' management efficiency ratios could be used to measure how well IQVIA Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IQVIA Holdings' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to climb to 0.06 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, IQVIA Holdings' Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.65 in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.7 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Keith Crandell | Twist Bioscience Corp | 58 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Xiaoying Mai | Twist Bioscience Corp | 30 | |
| Nelson Chai | Thermo Fisher Scientific | 55 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Aaref Hilaly | Guardant Health | 46 | |
| Arthur Bowman | Illumina | 69 | |
| Robert Hugin | Danaher | 61 | |
| James Healy | Natera Inc | 53 | |
| Walter Lohr | Danaher | 77 | |
| Brook Byers | Caredx Inc | 68 | |
| Roelof Botha | Natera Inc | 44 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
| Jonathan Sheena | Natera Inc | 45 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Paul Conley | Twist Bioscience Corp | 49 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| Ralph Snyderman | Caredx Inc | 78 | |
| Elias Zerhouni | Danaher | 69 | |
| Roy Baynes | Natera Inc | 63 | |
| R Keith | Thermo Fisher Scientific | 52 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0498 |
IQVIA Holdings Leadership Team
Elected by the shareholders, the IQVIA Holdings' board of directors comprises two types of representatives: IQVIA Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IQVIA. The board's role is to monitor IQVIA Holdings' management team and ensure that shareholders' interests are well served. IQVIA Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IQVIA Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ari Bousbib, Chairman of the Board, President, Chief Executive Officer | ||
| Michael Evanisko, Independent Director | ||
| Nicholas Childs, Senior Treasury | ||
| James Erlinger, Executive Vice President General Counsel, Secretary | ||
| John Danhakl, Independent Director | ||
| Trudy Stein, Chief VP | ||
| Andrea Spannheimer, Global Research | ||
| Richard III, President Solutions | ||
| Walter Staub, President - Research and Development Solutions | ||
| Michael McDonnell, Chief Financial Officer, Executive Vice President | ||
| Andrew Markwick, VP Relations | ||
| Carol Burt, Independent Director | ||
| Jon Resnick, President Canada | ||
| John Leonard, Lead Independent Director | ||
| Keriann Cherofsky, Corporate VP | ||
| Gregg Dearhammer, Safety Sciences | ||
| Cynthia Verst, President Innovation | ||
| Jeffrey MD, Global VP | ||
| James Fasano, Independent Director | ||
| Jonathan Coslet, Independent Director | ||
| Ronald Bruehlman, Interim Chief Financial Officer, Executive Vice President | ||
| Erlinger Sherbet, Executive Vice President General Counsel, Secretary | ||
| Jeffrey Spaeder, Global VP | ||
| John Connaughton, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Nilton Paletta, President America | ||
| Dennis Gillings, Lead Director | ||
| Todd Sisitsky, Independent Director | ||
| Jack Greenberg, Independent Director | ||
| Eric Sherbet, Executive Vice President General Counsel, Secretary | ||
| Richard Staub, President - Research and Development Solutions | ||
| Costa Panagos, President - Research & Development Solutions | ||
| Lucas Glass, Global Excellence | ||
| Rob Kotchie, President Solutions | ||
| Wendy Stewart, President Operations | ||
| Kerri Joseph, SVP Treasury | ||
| Jim Berkshire, Executive Operations | ||
| Alistair Grenfell, Middle Europe | ||
| Karl Guenault, Senior Officer | ||
| Ronald Rittenmeyer, Independent Director | ||
| Brian Mi, President Pacific | ||
| Kevin Knightly, President - Information and Technology Solutions |
IQVIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IQVIA Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0498 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 55.06 B | ||||
| Shares Outstanding | 182.01 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 92.28 % | ||||
| Number Of Shares Shorted | 2.85 M | ||||
| Price To Earning | 103.68 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IQVIA Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. For more information on how to buy IQVIA Stock please use our How to Invest in IQVIA Holdings guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for IQVIA Stock analysis
When running IQVIA Holdings' price analysis, check to measure IQVIA Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IQVIA Holdings is operating at the current time. Most of IQVIA Holdings' value examination focuses on studying past and present price action to predict the probability of IQVIA Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IQVIA Holdings' price. Additionally, you may evaluate how the addition of IQVIA Holdings to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is IQVIA Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IQVIA Holdings. If investors know IQVIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IQVIA Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.125 | Earnings Share 7.29 | Revenue Per Share 81.523 | Quarterly Revenue Growth 0.035 | Return On Assets 0.0498 |
The market value of IQVIA Holdings is measured differently than its book value, which is the value of IQVIA that is recorded on the company's balance sheet. Investors also form their own opinion of IQVIA Holdings' value that differs from its market value or its book value, called intrinsic value, which is IQVIA Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IQVIA Holdings' market value can be influenced by many factors that don't directly affect IQVIA Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IQVIA Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if IQVIA Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IQVIA Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.